Advertisement OTC allergy drug found to rival Singulair - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

OTC allergy drug found to rival Singulair

There is no significant difference between an over-the-counter decongestant and a prescription medication that costs almost four times as much in relieving hay fever symptoms, according to research carried out at the University of Chicago.

The 58-patient study compared the use of Pfizer’s non-prescription Sudafed (pseudoephedrine hydrochloride) with Merck & Co’s Singulair (montelukast sodium) in the treatment of hay fever and the relief of associated symptoms.

The study reached its conclusions having been supported in part by a medical school grant from Merck.

“This came as a genuine surprise,” said Dr Fuad Baroody, associate professor of surgery at the University of Chicago and director of the study. “Our hypothesis was that montelukast would have additional benefits and pseudoephedrine would interfere with sleep, but when we compared them head-to-head we found that for treatment of allergic rhinitis, these drugs at these doses were virtually identical.”

In fact, pseudoephedrine was found to have small advantages in specific categories. It was slightly more effective, for example, in reducing congestion, which it was specifically designed to do.

Dr Baroody noted, however, that a larger study would be needed for a definitive conclusion.